Celldex Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Celldex Therapeutics, Inc. (CLDX) develops novel antibody-based immunotherapies targeting mast cell-mediated inflammatory, allergic, and autoimmune diseases. The company's lead product candidate, barzolvolimab (CDX-0159), a humanized monoclonal antibody KIT antagonist, advances in Phase 3 trials for chronic spontaneous urticaria and Phase 2 trials for cold urticaria, symptomatic dermographism, prurigo nodularis, and atopic dermatitis; CDX-622, a TSLP/SCF bispecific antibody, progresses in Phase 1 healthy volunteer studies to deplete mast cells and inhibit Type 2 inflammation in broader inflammatory and fibrotic disorders. Founded in 1983 and headquartered in Hampton, New Jersey, Celldex operates primarily in the United States with a focus on clinical-stage biopharmaceutical development for immunology indications and targets patients with severe mast cell-driven conditions. Recent developments include positive Phase 3 data for barzolvolimab reinforcing its pipeline-in-a-product potential, a proposed public offering of common stock to fund ongoing trials, and third quarter 2025 financial results highlighting pipeline advancement amid strategic collaborations for commercialization support.
Company News
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
Head-To-Head Analysis: Senti Biosciences (NASDAQ:SNTI) and Celldex Therapeutics (NASDAQ:CLDX)
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Down – What’s Next?
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
Celldex's skin disease drug meets goals in two late-stage trials
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
Head-To-Head Survey: Celldex Therapeutics (NASDAQ:CLDX) & Bicycle Therapeutics (NASDAQ:BCYC)
Engineers Gate Manager LP Takes $1.26 Million Position in Celldex Therapeutics, Inc. $CLDX
Head-To-Head Comparison: Precigen (NASDAQ:PGEN) and Celldex Therapeutics (NASDAQ:CLDX)
Seres Therapeutics (NASDAQ:MCRB) and Celldex Therapeutics (NASDAQ:CLDX) Head to Head Review
Celldex to Present at Upcoming Investor Conference
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
California State Teachers Retirement System Acquires 21,233 Shares of Celldex Therapeutics, Inc. $CLDX
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss